

THE PRESENT USE AND THE POSSIBILITIES OF  
PHASE TRANSFER CATALYSIS IN DRUG SYNTHESIS

Pierre Cocagne<sup>a</sup>, José Elguero<sup>b</sup> and Roger Gallo<sup>a</sup>

<sup>a</sup> IPSOI, Fac Sciences & Tech. St Jérôme, rue H. Poincaré, 13013 Marseille, France

<sup>b</sup> C.S.I.C., Institute of Medicinal Chemistry, Juan de la Cierva 3, Madrid-6, Spain

**Abstract:** After a short introduction, the actual possibilities and the prospective use of phase transfer catalysis in drug preparation are reviewed (198 ref.)

CONTENTS

I. Introduction

1. Liquid-liquid Phase Transfer Catalysis
2. Solid-liquid Phase Transfer Catalysis
3. Triphase Catalysis

II. PTC classified according to the reaction type

1. Nucleophilic substitutions at saturated carbon
  - 1a. C-alkylations by NS Csp<sup>3</sup>
  - 1b. N-alkylations by NS Csp<sup>3</sup>
  - 1c. O-alkylations by NS Csp<sup>3</sup>
  - 1d. N,S-alkylations
2.  $\beta$ -Eliminations
3. Nucleophilic additions at unsaturated carbon
4. Nucleophilic substitutions at unsaturated carbon
  - 4a. Synthesis of esters
  - 4b. Synthesis of amides
5. Nucleophilic substitutions at aromatic molecules
6. Nucleophilic substitutions at heteroaromatic molecules
7. Oxidations
8. Reductions
9. Carbenes
10. Biphasic catalysis under acidic conditions
11. Reactions with organometallic catalysts

III. Conclusion

Glossary. - In reaction schemes the following terms are used:

PTC = Phase Transfer Catalysis

$Y^-$  = A nucleophilic anion, e.g.  $CN^-$ ,  $R_3C^-$ ,  $RO^-$ ,  $RCO_2^-$ ,  $F^-$ , ....

L = A leaving group, e.g. Cl, Br,  $OSO_2Me$ , ....

Z = An electron withdrawing group:  $NO_2$ , CN,  $CF_3$ , ....

$M^+$  = An alkaline or alkaline-earth cation:  $Na^+$ ,  $K^+$ ,  $Ca^{2+}$ , ....

$Q^+X^-$  = A quaternary ammonium or phosphonium halide.

Other substituents or atoms follow the IUPAC rules and their meaning is self evident.

The following *abbreviations* are frequently used:

TEBA = Triethyl benzyl ammonium chloride.

TEAB = Tetrabutyl ammonium bromide.

TBAHSO<sub>4</sub> = Tetrabutyl ammonium hydrogen sulfate.

TBACl = Tetrabutyl ammonium chloride.

18c6 = 18 crown 6.

Adogen or aliquat = A mixture containing mainly trioctyl methyl ammonium chloride.

## I. INTRODUCTION

Phase Transfer Catalysis is one of the most attractive new techniques in organic synthesis. The method has a very broad scope of application. Chemically, the possibilities include the preparation of compounds from starting materials unreactive or decomposed under other conditions, and more generally the increase of the yields or of the selectivities in a large number of syntheses. Moreover from a practical point of view the method is simple, the work up is easy, and the reagents and solvents are of low cost.

Several references have been published on the theory and practical uses of Phase Transfer Catalysis (books<sup>1-5</sup>; reviews<sup>6-12</sup>); they can be consulted for a listing of the reactions already reported. However, if general papers have appeared on the application of Phase Transfer Catalysis to several fields of chemistry, e.g. heterocyclic chemistry<sup>13</sup>, macromolecular chemistry<sup>14</sup>, industrial chemistry<sup>15</sup>, dye chemistry<sup>16</sup>, .. no reviews exist, to the best of our knowledge<sup>17</sup>, on the applications of phase transfer catalysis in Medicinal Chemistry, or more specifically to the synthesis of drugs or pharmaceutical intermediates. This is the purpose of the present paper.

Basically Phase Transfer Catalysis is a method which allows to carry out a reaction between a substrate soluble in an organic solvent and an ionic reagent insoluble in this solvent. Ionic reagents (saline compounds) are used in synthesis for two reasons:

- they exist as such and are not used under their neutral form, e.g. nitriles are prepared from a halide and NaCN not HCN<sup>18</sup>; aromatic fluorides are obtained by halogen exchange with KF not HF<sup>19</sup>.

- when the same reaction, e.g. a nucleophilic substitution, can be carried out either with a neutral or with an ionic nucleophile, the ionic species is always more reactive (by 10<sup>4</sup> to 10<sup>6</sup>)<sup>20</sup>, e.g. Na<sup>+</sup>RO<sup>-</sup> > ROH, Na<sup>+</sup>R<sub>2</sub>N<sup>-</sup> > R<sub>2</sub>NH, Na<sup>+</sup>RS<sup>-</sup> > RSH.

However, the heterogeneous conditions corresponding to the use of high concentrations of anionic nucleophiles in organic solvents lead to a poor contact between reagents and to low reaction rates.

A well documented method used to increase the mutual solubility of hydrophilic and lipophilic reagents is to carry out the reactions in protic solvents (in fact mostly hydroxylic) such as alcohols. However, when a nucleophilic anion is dissolved in a protic solvent it is always hydrogen bonded to the solvent and therefore its reactivity is greatly decreased.

Another class of compounds has attracted much interest: dipolar aprotic solvents<sup>21</sup>. The most commonly used are DMF, DMSO, HMPA, acetonitrile and nitromethane; they have the property to dissolve in part (if not completely) saline reagents without hydrogen bonding with them. Therefore they have the advantage to increase the rate of a large number of reactions<sup>22</sup>.


Unfortunately polar aprotic solvents have several inconveniences: they are expensive; they must be used under anhydrous conditions; they are difficult to remove from the reaction medium because of their high boiling points; they are miscible with water, which means that purification using aqueous solution must be avoided when upscaling chemical processes.

A method was really needed that would allow to dissolve ionic reagents in common apolar solvents, give easy and safe reaction conditions and afford increased yields of reaction and improved purity of compounds. Phase Transfer Catalysis meets all these conditions.

### 1. Liquid-Liquid Phase Transfer Catalysis


The following example, first reported by Starks, shows the possibilities of PTC<sup>23</sup>: if octyl chloride diluted in decane is reacted with sodium cyanide dissolved in water, at 105°C with a strong agitation, no reaction occurs after 3 hours. If 1.5% of hexadecyl tributyl phosphonium bromide is added, a 99% yield of octyl nitrile is obtained within 2 hours<sup>24</sup>.

The following scheme shows how the reaction proceeds when a tetrabutyl ammonium chloride is used as catalyst.




The sodium cyanide which is soluble in water does not migrate into the organic phase. Upon addition of a quaternary ammonium chloride, an exchange occurs in the aqueous phase between the cations  $\text{Na}^+$  and  $\text{Bu}_4\text{N}^+$ , and the ion pair  $\text{Bu}_4\text{N}^+\text{CN}^-$ , lipophilic enough because of the 16 carbons of the quaternary ammonium, transfers in the organic phase where the reactions take place.

Experimentally, liquid-liquid PTC corresponds to a system made of two phases: an organic phase containing a liquid reagent with (or without) an organic solvent non miscible in water and an aqueous phase containing in most cases a nucleophilic reagent  $\text{Y}^-\text{M}^+$ . Moreover a quaternary ammonium or phosphonium catalyst is partitioned between the two phases.



Depending upon the nature of the nucleophile two possibilities exist:

- $\text{M}^+\text{Y}^-$  is dissolved directly in water, e.g.  $\text{Na}^+\text{CN}^-$ ,  $\text{K}^+\text{F}^-$ , ...
- or  $\text{M}^+\text{Y}^-$  is obtained by exchange between a neutral reagent and a base,



In the last case the aqueous phase contains water and a concentrated base (usually  $\text{NaOH}/\text{H}_2\text{O}$ , 50/50 by weight).


The scheme reported above for synthesis of nitriles is a good representation of phase transfer mechanism when no additional base is necessary and when the quaternary ammonium salt is soluble in part in water. When an additional base is necessary in the aqueous phase or when the quaternary ammonium salt is not soluble in the aqueous phase, the mechanistic scheme may involve in addition an interfacial proton abstraction or an interfacial cation exchange<sup>1,9,23-30</sup>. These modifications of the basic PT mechanistic scheme may have practical consequences in the importance of agitation to obtain good yields of reaction.


Whatever the intimate mechanistic scheme, the activation of the anion is due to the exchange


of the paired counter cation and to the consequent solubilisation of a more reactive loose ion pair in a solvent of low polarity.

## 2. Solid-Liquid Phase Transfer Catalysis

Solid-liquid PTC corresponds experimentally to reactions occurring with an organic reagent soluble in a solvent and a solid substrate  $M^+Y^-$  insoluble in this solvent.


 : complexant:  
crown ether, cryptant,  
chelantant.




If a complexant  is added, the solid  $M^+Y^-$  is solubilized in the solvent and reacts under mild conditions.

In a specific example, potassium permanganate is added to a solution of benzene containing an olefin. Under these conditions the crystals of  $KMnO_4$  stand at the bottom of the flask, the solvent is colorless and no reaction occurs. If a small amount of 18 crown 6 is added, the solvent immediately turns purple (the permanganate dissolves) and the olefin is smoothly oxidized.


The complexants first used were the crown ethers, prepared by Pedersen<sup>31</sup>, which showed high complexing abilities of alkaline and alkaline earth cations<sup>32</sup> with the following properties:



18 crown 6



dibenzo 18 crown 6



dicyclohexyl 18 crown 6


a.- extraction of cations owing to the selective complexation which depends upon the size and the substitution of the macrocyclic ether<sup>33</sup>.

b.- activation of the anion paired to the complexed cation; the anion is said to be "naked"<sup>35</sup>.


Following the first series of crown ethers made by Pedersen<sup>31</sup> a tremendous amount of macrocyclic complexants have been synthesized in which structural parameters have been changed to obtain increased complexing abilities<sup>36-40</sup>.

Among all the new compounds prepared two series deserve a special mention:

- the *cryptates* made by Lehn et al have given an extra dimension (conceptually and practically) to the high complexing power of crown ethers<sup>11,41-44</sup>.




2,2,2-cryptate




1,1,1-cryptate


- the chiral host molecules designed by Cram *et al* have achieved splendid results in the separation of enantiomers and open new promises in asymmetric induction<sup>45,46</sup>.




On the other side open chain equivalents of crown ethers and cryptates have been prepared. They show a lower complexing activity than their closed ring equivalents, but they are efficient enough and far more easily prepared and consequently cheaper. Typical structures are glymes<sup>47-48</sup>, noncyclic polyether compounds<sup>49</sup>, polyethylene amines<sup>50,51</sup>, "polypodes"<sup>52,53</sup>, "octopus"<sup>54</sup>, "tridents"<sup>55,56</sup>, "lariat-ethers"<sup>57,58</sup>, etc.




glymes




noncyclic polyethers




polyethylene amines




"polypodes"




"octopus"



"tridents"



"lariat ethers"



Presently the majority of current syntheses is more likely to be carried out with liquid-liquid transfer conditions, with quaternary ammonium and phosphonium catalysts. Solid-liquid catalysis using complexants is still hampered by the high price of catalysts like crown-ethers or cryptates. In some cases, when water needs to be strictly avoided, reactions are conducted under solid-liquid conditions, with a quaternary ammonium or phosphonium catalyst (not a complexant). Moreover in order to solve the problem of catalyst recovery a new technique has been proposed: Triphase Catalysis.

### 3. Triphase Catalysis


This technique developed by Regen<sup>59-63</sup> is an extension of both liquid-liquid PTC and solid-liquid PTC. It makes use of biphasic organic-aqueous system and of a catalyst (quaternary salt, crown ether or glyme) supported on a polymeric backbone. The technique has the advantages of homo-











However, the  $pK_a$  associated with the dissociation of the  $CH_2$  protons of 25 is too high ( $pK_a \approx 30$ ) to allow the formation of an anion<sup>84</sup> and conversion of 25 to 26 under liq.-liq. PT conditions.

□ A starting material for the synthesis of alkaloids (Reissert compounds).

Alkylation of the Reissert compound 27a<sup>85</sup> followed by an alkaline hydrolysis affords an isoquinoline 27b used in the synthesis of alkaloids<sup>86</sup>.




#### 1b. N-alkylations by NSCsp<sup>3</sup>


The reactions described in this section are carried out with amines of low basicity where the nitrogen atom is bonded to electron withdrawing substituents or linked to (or included in) aromatic rings.

□ Last step in the synthesis of *phentolamine*, an  $\alpha$ -adrenergic blocking agent.

*Phentolamine* (30) can be prepared by alkylation of the aminophenol 28 with the halide 29<sup>87</sup>.




Similar alkylation reactions have been described with  $Ph_2NH$  using TEBA and NaOH with DMSO or HMPT,  $H_2O$ <sup>88</sup>.




□ Synthesis of substituted acridanones with anti-allergic and antiviral activities.

Acridanone derivatives 31 have been prepared<sup>89,90</sup> by alkylation reaction under PT conditions with TEBA and aqueous NaOH.




□ Last step in the synthesis of 1-(5-oxohexyl)theobromine, a vasodilator.

Reaction of sodium theobromine (32) with  $\text{Br}(\text{CH}_2)_4\text{COCH}_3$  in toluene and TBAB as catalyst affords the theobromine derivative 33<sup>91</sup>.




□ Key intermediate in the synthesis of *nocardicin A*, a  $\beta$ -lactam antibiotic.

Alkylation of the  $\beta$ -lactam 34 with *tert*-butyl- $\alpha$ -bromo-(*p*-methoxyphenyl)acetate with powdered KOH and TEBA gives *nocardicin A* (35). The optimum amount of catalyst is 2-10%, but  $\text{K}_2\text{CO}_3$  or  $\text{Et}_3\text{N}$  are not efficient<sup>92</sup>.




□ Potential interferon-inductor intermediate from glycosidation of a pyrimidine derivative<sup>93</sup>.

A regioselective *N*-7-glycosylation has been made when reacting a tri-*O*-benzyl-bromo-ribose (36) with a pyrimidine derivative 37 under PT conditions<sup>94</sup>.




□ Alkylation of benzodiazepine derivatives 38, potential anxiolytics.

The alkylation reaction is carried out in two steps; the first occurs at nitrogen and the second at carbon. Both substitutions are made under Phase Transfer conditions<sup>95</sup>.



□ Last step in the synthesis of *chlorpromazine*<sup>96</sup>, an antipsychotic.


Chlorophenothiazine 39 can be alkylated with  $\text{Cl}(\text{CH}_2)_3\text{NMe}_2$ , using sodium amide to give *chlorpromazine* (40)<sup>96</sup>. The same reaction has been carried out using aqueous NaOH and TEBA, affording *chlorpromazine* in good yields<sup>97</sup>.



□ Selective alkylation of adenine derivatives.


In most pharmaceutical applications, the compound substituted in position 9 is the most active isomer (41). However, alkylation under neutral conditions affords the 3-isomer (42). When the reaction is carried out under basic conditions (Na, EtOH) the 3-isomer is formed but the 9-isomer is the major component.

When the sodium or potassium salt of adenine is alkylated in a polar aprotic solvent: DMSO, DMF or HMPA, the 9-isomer is formed with 80-90% selectivity<sup>98</sup>. Using a method of alkylation of nucleosides and nucleotides, adenine has been methylated chiefly in position 9 by  $\text{CH}_3\text{Br}$  with TBAF (tetrabutylammonium fluoride in equimolar amount) in THF<sup>99</sup>. More recently a biphasic liq.-liq. method of alkylation of adenine has been described<sup>98</sup>; using aqueous NaOH and 5% of an ammonium salt (TEBA or Adogen), the 9-isomer was obtained as the major component. These studies indicate that beside providing simple and efficient synthetic procedures, PTC can modify completely the selectivity of alkylation reactions.



□ Synthesis of 2-alkylaminobenzophenones 44, synthetic intermediates in the manufacture of anxiolytics.

This is another interesting example of selective PT synthesis. The conventional methods of alkylation of 2-aminobenzophenones 43 are selective (mono versus dialkylation) only if a three-step process is used with formation of an intermediate sulfonamide<sup>100</sup> or secondary amide<sup>100</sup>. Otherwise direct alkylation with alkyl sulfate in acetic acid<sup>101</sup> or with polyphosphate esters<sup>102</sup> affords a mixture of mono- and di-alkylated derivatives. A PTC method<sup>103</sup> using powdered hydroxide and TBAB in THF, overcomes this difficulty and gives in one step a high yield of mono-alkylated derivative 44 (purity > 99%).




1c. O-alkylation by NSCsp<sup>3</sup>

O-alkylation of alcohols<sup>26,104</sup> and phenols<sup>105,106</sup> has been carried out by PTC. The results have been and will be extended to hydroxyl functionality on saturated, aromatic and heteroaromatic molecules.


□ Alkylation of hydroxybenzotriazoles, important in peptide synthesis.

1-Hydroxybenzotriazoles (45) are alkylated in good yields, at the oxygen atom, under PT conditions using TEACl as catalyst<sup>107</sup>.




□ Intermediate step in the synthesis of tyrosine derivatives, antidiuretic antagonists.

A synthesis of phenol ethers<sup>108</sup> has been adapted to the O-alkylation of protected (BOC) tyrosine methyl ester (46)<sup>109</sup> with isopropyl mesylate using PT the yield is 61%, whereas with other conventional methods it is very poor (4%).




□ Intermediate step in the synthesis of *propranolol* (β-adrenergic antagonist).

The O-alkylation of β-naphthol (47) by epichlorhydrin (48) under PT conditions affords an intermediate 49 of the synthesis of *propranolol* (50)<sup>110</sup>.



□ Last step in the synthesis of *pramoxine*, a local anesthetic<sup>111</sup>.


The previous PT etherifications may be extended to the alkylation of the ether 51 with *N*-(3-chloropropyl)morpholine to afford *pramoxine* (52).



On the other hand the direct synthesis of esters from alkali metal carboxylate and halides, under PT conditions<sup>112</sup> has been extended to the following reaction :

□ Intermediate step in the preparation of cephalosporins<sup>113</sup>.


When the alkali metal salts of benzyl carboxylate derivatives 53 are reacted with substituted benzyl halides 54, in an organic solvent containing a phase transfer catalyst, e.g.  $\text{Bu}_4\text{N}^+\text{Cl}^-$ , benzyl esters 55 are obtained which are useful as acylating agents for the preparation of antibiotics.



#### 1d. N,S-alkylations


□ Synthesis of hydantoin derivatives, having anticonvulsant activities.

The potassium salt of 5,5-diphenyl-2-thiohydantoin (56) has been alkylated with almost quantitative yields, under PT conditions giving a ratio 64/36 of isomers 58/57<sup>114</sup>.




Under conventional conditions using DME, the yield is moderate and the ratio 58/57 is reversed.

#### 2. $\beta$ -Eliminations



$\beta$ -Eliminations under phase transfer conditions, have been described using "hard" bases such as KOH, tBuOK or KF, with quaternary ammonium or phosphonium and crown ether catalysts<sup>115</sup>. Very little has appeared in Medicinal Chemistry but an interesting example is an intermediate step in the synthesis of polymeric support for biologically active polymers<sup>116</sup>: the preparation of p-chloromethylated styrene (60), by reaction of p-(2-bromoethyl)benzyl chloride (59) with potassium hydroxide is greatly improved using PT catalysts e.g. TBAB or 18 crown 6<sup>117</sup>.




#### 3. Nucleophilic Additions at Unsaturated Carbon (NACsp<sup>2</sup>)

They correspond mostly to addition of nucleophiles to carbonyl compounds or polarized double bonds, followed in some cases by elimination :




## 4a. Synthesis of esters by acylation of alcohols.

These reactions have been reported under PT conditions, in the acylation of carbohydrates<sup>128</sup>; the method is selective and a primary OH group of a sugar reacts preferably to a secondary OH<sup>129</sup>.



□ First step in the synthesis of *salsalate*, a latentiated form of salicylic acid.


By analogy, the PT technique may be used in the condensation of benzyl salicylate (65) with the acid chloride of salicylate benzyl ether (66) to produce a protected dimer 67, the direct precursor of *salsalate*<sup>130</sup>.



However, if the ester group of 65 were hydrolysed under aqueous liq.-liq. conditions, a solid-liq. technique, using powdered KOH<sup>131</sup>, may overcome this inconvenience.


## 4b. Synthesis of amides by acylation of amines.

Several indole derivatives have biological activities which are much dependent on the nature of substituents. In most cases the active molecules are substituted at the nitrogen atom by alkyl or acyl substituents. Therefore the PT acylation of indole (68), using powdered NaOH and quaternary ammonium salts, is of interest<sup>131</sup>.




□ Intermediate step in the synthesis of *indomethacin*, an antiinflammatory agent.

The tert-butyl ester of 2-methyl-5-methoxyindoleacetic acid (69) could be acylated under similar conditions with *p*-chlorobenzoyl chloride (70) to afford an intermediate 71 of *indomethacin* (72).




□ Intermediate step in the synthesis of *nitrazepam*, a sleep-inducing agent.

The reaction of 2-amino-5-nitrobenzophenone (73) with bromoacetyl bromide (74) affords the amide 75<sup>132</sup>. Selective monoalkylation of the primary amine in 73 could possibly be made with PT catalysis (cf. reference<sup>103</sup>).




### 5. Nucleophilic Substitution at Aromatic Molecules (NS Ar)

The reaction scheme for NS Ar is the following one :




The first reaction in these series where PTC has been used was described by Makosza *et al.*<sup>133, 134, 135</sup>; mostly phenylacetonitrile derivatives 76 have displaced leaving groups such as Cl and NO<sub>2</sub> on activated aromatics.




Besides phenylacetonitrile derivatives, other nucleophilic reagents have been used: phenols<sup>136, 137</sup>, alcohols<sup>138</sup>, sulfite<sup>139</sup> and fluoride<sup>140</sup>.

□ Synthesis of diphenyl ether derivatives.

The conditions of reference<sup>136</sup> are directly applicable to the preparation of a 4-nitrophenyl-phenyl ether (77)<sup>141</sup>




as well as to the synthesis of 2-nitrophenyl-4-chlorophenyl thioether (78)






□ Intermediate step in the synthesis of thyroxine, a thyroid hormone<sup>142</sup>.

The benzenesulfonate 79 is also suited for nucleophilic aromatic substitutions under PT conditions, since the  $\text{SO}_2\text{Ph}$  leaving group is activated by the ortho nitro as well as the para carbonyl group. Treatment of 79 with the anion of the monophenyl ether of hydroquinone gives the substituted diphenyl ether 80, precursor of thyroxine.



□ First step of the synthesis of *dapsone*, an antileprosy drug<sup>143</sup>.

The synthesis of *dapsone*, starting with aromatic nucleophilic substitution of the sodium salt of the sulfonic acid 81 on *p*-chloronitrobenzene affords the sulfone 82. This reaction may be carried out using PTC, provided appropriate conditions are found.




One should remember that all the studies on Phase Transfer Catalysis applied to aromatic substitutions show a chemical limit : the leaving groups on benzene derivatives need to be activated by at least one electron-withdrawing substituent on the ring.

## 6. Nucleophilic Substitutions at Heteroaromatic Molecules (NS Het)

An earlier example of halide exchange with KF on pentachloropyridine was reported using a 2,2,2-cryptate catalyst<sup>144</sup>.



Analogous reactions have been carried out with derivatives of phenylacetonitrile and 9-chloroacridine (83)<sup>145</sup>, 2-chloroquinoline (84)<sup>146</sup> and 2-chloro-3-(or 5)nitropyridine (85)<sup>147,148</sup>.




Besides carbanions, other nucleophiles have been used : alcohols<sup>149</sup>, phenols<sup>150</sup>, phthalamide<sup>151</sup> and cyanide<sup>152</sup>.

□ Intermediate step in the synthesis of antihypertensive agents.


The introduction of a  $\beta$ -adrenergic blocking moiety 86 on 2-chloro-3-cyanopyridine (87) has been carried out under PT conditions, which proved superior to the conventional procedure using NaH/DMF,

to afford an intermediate 88 in the preparation of antihypertensive agents<sup>149</sup>.




□ Intermediate step in the synthesis of phenyl-(2-pyridyl)-acetonitrile derivatives.

The addition of phenylacetonitrile to 2-bromopyridine using hard bases, such as  $\text{NaNH}_2$ <sup>153</sup>, affords a molecule 89 which is the intermediate in the preparation of several active agents,




e.g. *disopyramide* (90, an antiarrhythmic)<sup>154</sup> and *methylphenidate* (91, an analeptic)<sup>155</sup>.



The preparation of the intermediate 89 could be carried out under PT conditions, unfortunately the method fails when using liq.-liq. conditions<sup>150</sup>.

□ Synthesis of pyrimidine derivatives with antitumor properties.


The halogen exchange using KF and a bromo derivative of pyrimidine 92 has been carried out with 18 crown 6 in acetonitrile and affords the derivative 93<sup>156</sup>, 2',3',5'-tris-O-acetyl-8-fluoro-adenosine.



7. Oxidations


Phase Transfer Catalysis is a convenient and efficient technique for oxidation of organic compounds under mild conditions. The following is a sample of references corresponding to oxidizing systems working under PT conditions : permanganate with quaternary ammonium salt (TCMA or TBAB)<sup>157</sup> or dicyclohexyl 18 crown 6<sup>158</sup>; chromate, mainly with the  $\text{HCrO}_4^-$  form of a resin-bound quaternary cation<sup>159</sup>; hypochlorite<sup>160</sup>; osmium tetroxide and ruthenium tetroxide as cocatalysts with other oxidizing systems<sup>161</sup>; superoxide<sup>162</sup>, and peroxides<sup>163</sup>. The molecules oxidized include terminal olefins (into carboxylic acids), internal olefins (into diols), primary alcohols (into carboxylic acids), secondary alcohols (into ketones), benzyl alcohols (into benzaldehydes),...

An interesting application of PTC to the oxidation of organic molecules is the conversion of substituted phenylacetonitriles 94 to phenylketones 95<sup>164,165</sup>.




□ First step in the synthesis of *oxoethazine*, a local anesthetic.

The synthesis reported<sup>166</sup> starts with the Friedel-Crafts acylation of benzene with isobutyryl chloride to give the ketone 96.




An alternative method could involve alkylation of phenylacetonitrile (94, R = H to R = iPr) followed by oxidation; both steps can be run under PT conditions.




□ Intermediate step in the synthesis of a highly potent estrogen.

During a recent synthesis of an estrogen, a PT oxygenation of the intermediate cyanoestratriene has been reported<sup>167</sup>.


 8. Reductions

The use of Phase Transfer Catalysis in reductions with common complex hydrides such as  $\text{LiAlH}_4$  or  $\text{NaBH}_4$  seems very promising. However, the study of the mechanism of reduction using  $\text{LiAlH}_4$  shows the importance of the electrophilic catalysis of the cation  $\text{Li}^+$ <sup>168,169</sup>.




Therefore the introduction of a cryptate in the course of the reduction of cyclohexanone by  $\text{LiAlH}_4$  completely suppresses the reaction.

On the other hand, the presence of Aliquat increases the rate of reduction of ketones when using  $\text{NaBH}_4$  in aqueous  $\text{NaOH}$ <sup>24</sup>. Tetraalkylammonium borohydrides are also reported as reducing agents in apolar solvents<sup>170,171</sup>. The best results in the reduction of ketones to alcohols, using tetraalkylammonium ions to transfer  $\text{BH}_4^-$  from aqueous to organic phase, have been obtained with salts containing a hydroxylic group on the carbon  $\beta$  to the nitrogen atom<sup>66,172,173</sup>.


□ Last step in the synthesis of *epinephrine*.

The reduction with borohydride using PT conditions may be extended to the ketone 97 in order to obtain the amino alcohol 98 which is resolved as the tartrate salt to afford the (-) isomer of *epinephrine*.




□ Last step in the synthesis of *metaraminol*, used to raise blood pressure.

Formation of the Schiff base of compound 99 gives an intermediate 100 which is reduced to the corresponding amine 101; the drug is the (-) isomer<sup>175</sup>.



The reduction step 100 $\rightarrow$ 101 is very similar to the following reaction carried out under PT conditions with  $\text{NaBH}_4$ <sup>176</sup>.



## 9. Carbenes

The preparation of dichlorocarbene under biphasic conditions was published by Makosza in 1969<sup>177</sup>. Using a reservoir of 50% aqueous  $\text{NaOH}$  and chloroform he was able to obtain a high yield of dichlorocyclopropanation of an olefin.


This method is clearly superior to previous procedures which involved sodium ethoxide or potassium *tert*-butoxide in anhydrous solvents<sup>178</sup>.

Besides the liq.-liq. two phase method described by Makosza and Starks<sup>179</sup>, a solid-liquid method may be preferred to prevent the hydrolysis of the carbene, when compounds of low reactivity are used<sup>180</sup>.

Dichlorocarbenes prepared under PT conditions have been involved in the following reactions:


□ Preparation of an azepine derivative, intermediate in the synthesis of psychotropic drugs.

The synthesis of the intermediate 103 has been achieved<sup>181</sup> by addition to the double bond of 102 and insertion in the NH bond of two molecules of dichlorocarbene prepared under PT conditions (the  $\text{CHCl}_2$  on the nitrogen atom being hydrolysed to the formyl functionality).



□ Preparation of adamantane derivatives.

Adamantane derivatives are found in several families of substances recognized as drugs<sup>182</sup>. The adamantane moiety has been used to increase the lipophilic character of these compounds. Therefore, the easy introduction of a functionality in the adamantane molecule may help to build up a more complex structure. This is the case with the reaction of adamantane with chloroform under PT conditions which gives an insertion of dichlorocarbene into a tertiary CH bond<sup>183</sup>.




#### 10. Biphasic Catalysis under Acidic Conditions


All the syntheses reported up to this point involve the transfer of nucleophilic reagents under basic or neutral conditions. A few references correspond to reactions run under acidic conditions. More fundamentally it would be of interest to extend biphasic catalysis to the transfer of protons or positively charged electrophiles from an aqueous solution to an apolar solvent. For this purpose two main types of systems have been described in the literature.

a- Systems using a standard quaternary ammonium or phosphonium catalyst which transports a proton from an aqueous acidic solution to an organic phase and catalyses the following reactions:


▲ Conversion of primary alcohols to alkyl bromides<sup>184</sup>.




▲ Cleavage of ethers<sup>185</sup>.




▲ Addition of hydricids to alkenes<sup>186</sup>.



▲ Acid hydrolysis of carboxylic esters<sup>187</sup>.



The origin of the catalytic effect is probably due to an extraction of HX, associated to a quaternary salt, from water to the organic solvent<sup>188</sup>.



b- Systems using a phase transfer catalyst with a lipophilic anion (not cation). The process being a "negative picture" of the classical PT catalysis with exchange of anions and transfer of the proton or of the electrophile. Under that heading have been described:

▲ Hydrolysis of esters using tetraphenyl borate,  $\text{Na}^+\text{BPh}_4^-$ <sup>189</sup>.

▲ Azo coupling with transfer of a diazonium ion associated to a dodecylbenzenesulfonate obtained from:  $\text{Na}^+\text{O}_3\text{SC}_6\text{H}_4\text{C}_{12}\text{H}_{23}$ <sup>191</sup>.


▲ Azo coupling or Friedel-Crafts alkylations with stable tetrakis[3,5-di(Fmethyl)phenyl borate] (TFPB)<sup>192,193</sup>.

Very little has been specifically applied to the synthesis of pharmaceutical intermediates but the potentiality of the method is real.


### 11. Reactions with Organometallic Catalysts

A new very promising area, where PTC will undoubtedly find important applications, is transition metal chemistry. Two recent reviews have been published on the subject<sup>194,195</sup> and the following are typical reactions related to that topic.


▲ Carbonylation of organic halides<sup>196,197</sup>.



▲ Substitution of aromatic halides<sup>194</sup>.



▲ Reduction of nitro compounds<sup>198</sup>.



Almost certainly several reactions combining transition metal and Phase Transfer Catalysis will find new applications in drug synthesis.

## III. CONCLUSION

In conclusion, the possibilities of Phase Transfer Catalysis in the synthesis of drugs are enormous. Owing to its high chemical versatility and economical advantages the technique will find applications in both academic and industrial laboratories. Presently the interest in the method is extremely high and in the coming years a vast amount of patent and journals literature will be published. We hope that the presentation of this review, which follows a mechanistic guideline will help to rationalize the results already reported, to better design new synthesis, and to open new promises in the use of PTC in drug synthesis.

## REFERENCES

1. E.V. Dehmlow and S.S. Dehmlow, 'Phase Transfer Catalysis', Springer Verlag, Weinheim, 1980.
2. C.M. Starks and C. Liotta, 'Phase Transfer Catalysis', Academic Press, New York, 1978.
3. W.P. Weber and G.W. Gokel, 'Phase Transfer Catalysis in Organic Synthesis', Springer Verlag, Berlin, 1977.
4. W.E. Keller, 'Compendium of Phase Transfer Reactions', Fluka, Buchs, 1979.
5. A. Brandström, 'Preparative Ion Pair Extraction', Apotekarsocieteten, Stockholm, 1976.
6. J. Dockx, *Synthesis*, 1973, 441.
7. G.W. Gokel and W.P. Weber, *J. Chem. Ed.*, 1978, 55, 350.
8. W.P. Weber and G.W. Gokel, *J. Chem. Ed.*, 1978, 55, 429.
9. M. Makosza, *Pure App. Chem.*, 1975, 43, 439.
10. J.M. McIntosh, *J. Chem. Ed.*, 1978, 55, 235.
11. J.M. Lehn, *Acc. Chem. Res.*, 1978, 11, 49.
12. E.V. Dehmlow, *Angew. Chem., Int. Ed. Eng.*, 1977, 16, 493.
13. R. Gallo, H. Dou and P. Hassanaly, *Bull. Soc. Chim. Belg.*, 1981, 90, 849.
14. E. Chiellini, R. Solaro and S. d'Antone, *Makromol. Chem.*, 1981, 82.
15. B. Reuben and K. Sjöberg, *Chem. Tech.*, 1981, 315.
16. E.V. Dehmlow, *Chimica*, 1980, 34, 12.
17. Except a good introductory paper on 'Phase Transfer Catalysis in the Production of Pharmaceuticals', by L. Lindblom and M. Elander, *Pharm. Tech.*, 1980, 59.
18. D.T. Mowry, *Chem. Rev.*, 1948, 42, 189.
19. A.K. Barbour, L.J. Belf and M.W. Buxton, *Adv. Fluorine Chem.*, 1963, 3, 181.
20. When rate constants are measured with small concentrations of nucleophiles under homogeneous conditions: R.G. Pearson and J. Songstad, *J. Am. Chem. Soc.*, 1967, 89, 1827; C.D. Ritchie, *J. Am. Chem. Soc.*, 1975, 97, 1170.
21. a) A.J. Parker, *Quart. Rev.*, 1962, 163; b) B. Tchoubar, *Bull. Soc. Chim. Fr.*, 1964, 2069.
22. For a sampling of syntheses improved by using dipolar aprotic solvents see: L. Fieser and M. Fieser, 'Reagents for Organic Synthesis', Vol. I-VII, John Wiley, New York.
23. C.M. Starks and R.M. Owens, *J. Am. Chem. Soc.*, 1973, 95, 3613.
24. C.M. Starks, *J. Am. Chem. Soc.*, 1971, 93, 195.
25. D. Landini, A.M. Maia and F. Montanari, *J. Am. Chem. Soc.*, 1978, 100, 2796.
26. H.H. Freedman and R.A. Dubois, *Tetrahedron Lett.*, 1975, 3251.
27. J.E. Gordon and R.E. Kutina, *J. Am. Chem. Soc.*, 1977, 99, 3903.
28. D. Landini, A. Maia and F. Montanari, *J. Chem. Soc., Chem. Commun.*, 1977, 112.
29. A. Brandström, *Acta Chem. Scand.*, 1976, 30B, 203.
30. M. Makosza and E. Bialecka, *Tetrahedron Lett.*, 1977, 183.

31. C.J. Pedersen, *J. Am. Chem. Soc.*, 1967, 89, 2495 & 7017.
32. C.J. Pedersen and H.K. Frensdorff, *Angew. Chem., Int. Ed. Engl.*, 1972, 11, 16.
33. In that respect the analogy of behavior of crown ethers and of antibiotics such as valinomycin, enniatin A or nonactin should be stressed<sup>34</sup>.
34. a) C. Moore and B.C. Pressman, *Biochem. Biophys. Res. Commun.*, 1964, 15, 562; b) Y.A. Ovchinnikov and V.T. Ivanov, *Tetrahedron*, 1975, 31, 2177; c) D.E. Fenton, *Chem. Soc. Rev.*, 1977, 6, 325; d) A. Samat, M.E.M. Bibout, M. Chanon and J. Elguero, *Nouveau J. Chim.*, 1982, 6, 483.
35. G.W. Gokel and H.D. Durst, *Synthesis*, 1976, 168, see however, J.M. Miller and J.H. Clark, *J. Chem. Soc., Chem. Commun.*, 1982, 1318.
36. J.J. Christensen, D.J. Eatough and R.M. Izatt, *Science*, 1974, 174, 351.
37. A.C. Knipe, *J. Chem. Ed.*, 1976, 53, 618.
38. E. Weber and F. Vögtle, *Topics Current Chem.*, 1981, 98, 1.
39. F. Dejong and D.N. Reinhoudt, *Adv. Phys. Org. Chem.*, 1980, 17, 279.
40. J.S. Bradshaw and P.E. Stott, *Tetrahedron*, 1980, 36, 461.
41. B. Dietrich, J.M. Lehn and J.P. Sauvage, *Tetrahedron Lett.*, 1969, 2885.
42. J. M. Lehn, *Pure and Appl. Chem.*, 1977, 49, 857.
43. J.M. Lehn, *Pure and Appl. Chem.*, 1978, 50, 871.
44. J.M. Lehn, *Pure and Appl. Chem.*, 1981, 52, 2241.
45. D.J. Cram and J.M. Cram, *Science*, 1974, 183, 803.
46. D.J. Cram and J.M. Cram, *Acc. Chem. Res.*, 1978, 11, 8.
47. K. Yoshikagu and S.L. Regen, *J. Org. Chem.*, 1982, 47, 2493.
48. D.G. Lee and V.S. Chang, *J. Org. Chem.*, 1978, 43, 1532.
49. K. Hiratani, *Chem. Lett.*, 1982, 1021.
50. H. Normant, T. Cuvigny and P. Savignac, *Synthesis*, 1975, 805.
51. S. Farhat, R. Gallo and J. Metzger, *C.R. Acad. Sci. Paris*, 1978, 287C, 581.
52. M. Cinquini, F. Montanari and P. Tundo, *J. Chem. Soc., Chem. Commun.*, 1974, 878.
53. R. Fornasier and F. Montanari, *Tetrahedron Lett.*, 1976, 1381.
54. F. Vögtle and E. Weber, *Angew. Chem.*, 1974, 86, 896.
55. G. Soula, *Eur. Pat.*, 016,673 (Feb 22, 1980).
56. G. Soula and L. Linguenheld, *Fr. demande*, 79.11100 (May 3, 1979).
57. R.A. Schultz, D.M. Dishong and G.W. Gokel, *J. Am. Chem. Soc.*, 1982, 104, 625.
58. D.M. Dishong, C.J. Diamond and G.W. Gokel, *Tetrahedron Lett.*, 1981, 1663.
59. S.L. Regen, *J. Am. Chem. Soc.*, 1976, 98, 6270.
60. S.L. Regen, *J. Am. Chem. Soc.*, 1977, 99, 3838.
61. S.L. Regen and L. Dulak, *J. Am. Chem. Soc.*, 1977, 99, 623.
62. S.L. Regen, D. Bolikal and C. Barcelon, *J. Org. Chem.*, 1981, 46, 2511.
63. For a review see: S.L. Regen, *Angew. Chem., Int. Ed. Engl.*, 1979, 18, 421.
64. D. Lednicer and L.A. Mitscher, 'The Organic Chemistry of Drug Synthesis', John Wiley, New York, 1977.
65. Ref. 64, p. 67.
66. S. Colonna and R. Fornasier, *Synthesis*, 1975, 531.
67. D. Landini, F. Montanari and F. Rolla, *Synthesis*, 1974, 37.
68. According to E.V. Dehmow (ref.<sup>1</sup>) there is only a small improvement in the synthesis of bromides from alcohols and aqueous HBr using ammonium catalysts. D. Landini *et al.*<sup>67</sup> describe the synthesis of chlorides from alcohols.



69. A. Lespagnol, 'Précis de Pharmacie Chimique Usuelle', Technique et Documentation, Paris, 1977.
70. C.H. Tilford, M.G. VanCampen and R.S. Shelton, *J. Am. Chem. Soc.*, 1947, 69, 3902.
71. M. Makosza and B. Serafinova, *Rocz. Chem.*, 1966, 40, 1647.
72. Ref. 64, p. 149.
73. E.M. Schultz, C.M. Robbard and J.M. Sprague, *J. Am. Chem. Soc.*, 1967, 69, 188.
74. M. Bockmühl and G. Ehrhardt, *Liebigs Ann. Chem.*, 1949, 52, 561.
75. J.J. Taylor, U.S. Patent 4,242,274 (Dec 30, 1980).
76. J.H. Poupaert, P. Van der Jengd, B.M. Gerardy, M. Claesen and P. Dumont, *J. Chem. Res. (S)*, 1981, 192.
77. B. Capon, *Quart. Rev.*, 1964, 18, 45.
78. W. Stuhmer and S. Franke, U.S. Patent 2,934,557 (1960).
79. E.J. Corey, T. Ravindranathan and S. Terashima, *J. Am. Chem. Soc.*, 1971, 93, 4326.
80. M. Makosza, Pol. Pat., 55,571 (1968); *Chem. Abstr.*, 1969, 70, 106047E.
81. I.I. Harrison, B. Lewis, P. Nelson, W. Rooks, A. Roszkowski, A. Tomalonis and J.H. Fried, *J. Med. Chem.*, 1970, 13, 203.
82. A. Jończyk, M. Ludwikow and M. Makosza, *Rocz. Chem.*, 1973, 47, 89.
83. N. Sperber and D. Papa, U.S. Patent 2,567,245 (1951).
84. A. Strelwieser, W.B. Hollyhead, G. Sonnicksen, A.H. Pudjaatmaka, C.J. Chang and T.L. Krüger, *J. Am. Chem. Soc.*, 1971, 93, 5096.
85. M. Makosza, *Tetrahedron Lett.*, 1969, 677.
86. F.D. Popp, *Adv. Heterocyclic Chem.*, 1968, 9, 1.
87. Ref. 64, p. 243.
88. A. Jonczyk and M. Makosza, *Rocz. Chem.*, 1975, 49, 1203.
89. J.P. Galy, J. Elguero, E.J. Vincent, A.M. Galy and J. Barbe, *Synthesis*, 1979, 944.
90. H. Nishi, H. Kohno and T. Kano, *Bull. Chem. Soc. Japan*, 1981, 54, 1897.
91. Iwashiro Seiyaku Cie, Jap. Kokai, 81 61,380 (May 26 1981).
92. P.G. Mattingly and M.J. Miller, *J. Org. Chem.*, 1981, 46, 1557.
93. P.F. Torrence, E. Declercq, J.A. Waters and B. Witkop, *Biochemistry*, 1974, 13, 4400.
94. F. Seela and D. Hasselmann, *Chem. Ber.*, 1980, 113, 3389.
95. G. Vernin, H. Domloj, C. Siv, J. Metzger, A. Archavlis and J.R. Llinas, *Chem. Scripta*, 1980, 16, 157.
96. P. Charpentier, P. Cailliot, R. Jacob, J. Gandechon and P. Buisson, *C.R. Acad. Sci. Paris*, 1952, 235, 59.
97. J. Massé, *Synthesis*, 1977, 341.
98. I. Shinkai, M.C. Van der Zwan, F.W. Hartner, R.A. Reamer, R.J. Tull and I.M. Weinstock, *J. Het. Chem.*, 1981, 18, 197.
99. K.K. Ogilvie, S.L. Beaucage and M.F. Gillen, *Tetrahedron Lett.*, 1978, 1663.
100. L.H. Sternbach, R.I. Frier, W. Metksics, G. Sachs and A. Stempel, *J. Org. Chem.*, 1962, 27, 3781.
101. E.B. Åkerblom, French Patent 2,081,393 (1972).
102. M. Oklobdzija, V. Sunjic, F. Kajfez, V. Caplar and D. Kolbah, *Synthesis*, 1975, 596.
103. G. Mouzin, H. Cousse and J.M. Autin, *Synthesis*, 1981, 448.
104. A. Merz, *Angew. Chem., Int. Ed. Engl.*, 1973, 12, 846.
105. A. McKillop, J.C. Fiaud and R.P. Hug, *Tetrahedron*, 1974, 30, 1379.
106. E. D'Incan and P. Viout, *Tetrahedron*, 1975, 31, 159.
107. W.A. Feld, R.J. Paessun and M.P. Serve, *J. Macromol. Sci. Chem.*, 1981, A15, 891.

108. M. Fedorynski, K. Wojciechowski, Z. Matacz and M. Makosza, *J. Org. Chem.*, 1978, 43, 4682.
109. A.M. Kolodziejczyk and M. Manning, *J. Org. Chem.*, 1981, 46, 1944.
110. H. Shinozaki, N. Yoshida and M. Tajima, *Chem. Lett.*, 1980, 7, 869.
111. J.W. Wilson, C.L. Zirkle, E.L. Anderson, J.J. Stehle and G.E. Ulliyot, *J. Org. Chem.*, 1951, 16, 792.
112. H.E. Hennis, J.P. Easterly, L.R. Collins and L.R. Thompson, *Ind. Eng. Chem. Prod. Res. Dev.*, 1967, 6, 193.
113. J.M. Greene and C.A. Bunnell, *Eur. Pat.*, 51,457 (May 12, 1982).
114. K. Kieckonowicz, A. Zejc, M. Mikolajczyk, A. Zatorski, J. Karolak and W.W. Wieczorek, *Tetrahedron*, 1981, 37, 409.
115. For typical references see: E.V. Dehmlow and M. Lissel, *Tetrahedron*, 1981, 37, 1653; D. Landini *et al.*, *Synthesis*, 1974, 428; several patents exist on that topic.
116. M. Okawara, K. Takemoto and J. Harada, 'Organic Syntheses Using Polymers', Kodansha Ed., Tokyo, 1976.
117. T. Nishikubo, T. Iizawa, K. Kobayashi and M. Okawara, *Tetrahedron Lett.*, 1981, 3873.
118. V. Dryanska and C. Ivanov, *Tetrahedron Lett.*, 1975, 3519.
119. G. Cardillo, D. Savoia and A. Umani-Ronchi, *Synthesis*, 1975, 453.
120. S. Juliá and A. Ginebreda, *Afinidad*, 1980, 37, 194.
121. A. Jonczyk, M. Fedorynski and A. Makosza, *Tetrahedron Lett.*, 1972, 2395.
122. E. d'Incan and J. Seyden-Penne, *C.R. Acad. Sci. Paris*, 1975, 281C, 1031.
123. T. Yamada and M. Ohki, *Synthesis*, 1981, 631.
124. G.R. Kieczkowski, C.S. Pogonowski, J.E. Richman and R.M. Schlessinger, *J. Org. Chem.*, 1977, 42, 175.
125. Y.A. Zhdanov, Y.E. Alekseev, G.V. Zinchenko and S.S. Dorochenko, *Dokl. Akad. Nauk. SSSR*, 1976, 231, 868.
126. J. M. McIntosh, *Canad. J. Chem.*, 1977, 55, 4200.
127. C. Harries, *Liebigs Ann. Chem.*, 1903, 328, 322.
128. W. Szeja, *Pol. J. Chem.*, 1980, 54, 1301.
129. W. Szeja, *Pol. J. Chem.*, 1980, 54, 1323.
130. Ref. 64, Vol. 2, p. 90.
131. V.O. Illi, *Synthesis*, 1979, 387.
132. L.H. Sternbach, R.I. Fryer, O. Keller, W. Metlesics, G. Sachs and N. Steiger, *J. Med. Chem.*, 1963, 6, 261.
133. M. Makosza, *Tetrahedron Lett.*, 1969, 673.
134. M. Makosza and M. Ludwikow, *Bull. Acad. Pol. Sci.*, 1971, 19, 231.
135. M. Makosza, M. Jagusztyn-Grochowska, M. Ludwikow and M. Jawdosink, *Tetrahedron*, 1974, 30, 3723.
136. Ciba-Geigy, *Belg. Pat.*, 841,726 (1976).
137. K.J. Kolonko, M.L. Deinzer and T.L. Miller, *Synthesis*, 1981, 133.
138. P.M. Quann and S.R. Korn, *Ger. Offen.*, 2,634,419 (1977).
139. M. Gisler and H. Zollinger, *Angew. Chem., Int. Ed. Engl.*, 1981, 20, 203.
140. C.L. Liotta and H.P. Harris, *J. Am. Chem. Soc.*, 1974, 96, 2250.
141. Ref. 69, p. 29.
142. Ref. 64, p. 96.

143. H. Bauer, *J. Am. Chem. Soc.*, 1939, 61, 617.
144. M. Gross and F. Peter, *Bull. Soc. Chim. Fr.*, 1975, 871.
145. M. Wilczynski, M. Jawdosink and M. Makosza, *Rocz. Chem.*, 1977, 51, 1643.
146. M. Jawdosink, M. Lućwikow and B. Bednarska, *Pol. J. Chem.*, 1979, 53, 85.
147. M. Jawdosink, M. Makosza, E. Malinowska and W. Wilczynski, *Pol. J. Chem.*, 1978, 52, 2189.
148. H. Alsaïdi, R. Gallo and J. Metzger, *C.R. Acad. Sci. Paris*, 1979, 289C, 203.
149. A.J. Serioduggan, E.J. Grabowski and W.K. Russ, *Synthesis*, 1980, 573.
150. H. Alsaïdi, R. Gallo and J. Metzger, *Synthesis*, 1980, 921.
151. W. Rasshofer and F. Vögtle, *Tetrahedron Lett.*, 1979, 1217.
152. K. Hermann and G. Simchen, *Liebigs Ann. Chem.*, 1981, 333.
153. A. Kleemann, *Chem. Zeit.*, 1977, 101, 389.
154. a) Searle & Co, US Pat., 3,225,054 (Dec. 21, 1965); b) Farbwerke Hoechst A.-G., Ger. Offen., 830,193 (Feb. 4, 1952); c) Schering Co, US Pat., 2,567,245 (Sept. 11, 1951).
155. L. Panizzon, *Helv. Chim. Acta*, 1944, 27, 1748.
156. Y. Kobayashi, I. Kumadaki, A. Ohsawa and S. Murakami, *J. Chem. Soc., Chem. Commun.*, 1976, 430.
157. A.W. Herriott and D. Picker, *Tetrahedron Lett.*, 1974, 1511.
158. D. Sam and H.E. Simmons, *J. Am. Chem. Soc.*, 1972, 94, 4024.
159. G. Cainelli, G. Cardillo, M. Orena and S. Sandri, *J. Am. Chem. Soc.*, 1976, 98, 6737.
160. G.A. Lee and H.H. Freedman, *Tetrahedron Lett.*, 1976, 1641.
161. Ref. 2, pp. 307-311.
162. J. Sanfilippo, C. Chern and J.S. Valentine, *J. Org. Chem.*, 1976, 41, 1077.
163. C.R. Harrison and P. Hodge, *J. Chem. Soc., Perkin Trans. I*, 1976, 605.
164. Y. Masuama, Y. Meno and M. Okawara, *Chem. Lett.*, 1977, 1439.
165. A. Donetti, O. Boniardi and A. Ezhaya, *Synthesis*, 1980, 1009.
166. J. Seifter, R.S. Hanslick and M.E. Freed, U.S. Pat., 2,780,646 (1957).
167. G. Sauer, U. Eder, G. Hafler, G. Neef, R. Wiechert and D. Rosenberg, *Liebigs Ann. Chem.*, 1982, 459.
168. J.L. Pierre and H. Handel, *Tetrahedron Lett.*, 1974, 2317.
169. A. Loupy, J. Seyden-Penne and B. Tchoubar, *Tetrahedron Lett.*, 1976, 1677.
170. E.A. Sullivan and A.A. Hinckley, *J. Org. Chem.*, 1962, 27, 3731.
171. A. Brandström, U. Junggren and B. Lamm, *Tetrahedron Lett.*, 1972, 3173.
172. J. Balcells, S. Colonna and R. Fornasier, *Synthesis*, 1976, 266.
173. J.P. Massé and E.R. Parayre, *J. Chem. Soc. Chem. Commun.*, 1976, 438.
174. Ref. 64, p. 63.
175. Ref. 64, p. 68.
176. L. Horner and W. Brich, *Liebigs Ann. Chem.*, 1978, 710.
177. M. Makosza and M. Wawryniewicz, *Tetrahedron Lett.*, 1969, 4659.
178. W.E. Parham and E.E. Schweizer, *Org. React.*, 1963, 13, 55.
179. Ref. 2, p. 224.
180. S. Juliá and A. Ginebreda, *Synthesis*, 1977, 682.
181. K. Kawashima, T. Saraie, Y. Kawano and T. Ishiguro, *Chem. Pharm. Bull. (Tokyo)*, 1978, 26, 942.
182. R.C. Fort, 'Adamantane. The Chemistry of Diamond Molecules', Marcel Dekker, New York, 1967.
183. I. Tabushi, Z. Yoshida and N. Takahashi, *J. Am. Chem. Soc.*, 1970, 92, 6670.
184. D. Landini, F. Montanari and F. Rolla, *Synthesis*, 1974, 37.

185. D. Landini, F. Montanari and F. Rolla, *Synthesis*, 1978, 771.
186. D. Landini and F. Rolla, *J. Org. Chem.*, 1980, 45, 3527.
187. D. Landini and F. Rolla, *J. Org. Chem.*, 1982, 47, 154.
188. E.V. Dehmlow and M. Slopauka, *Chem. Ber.*, 1979, 112, 2765.
189. D.W. Armstrong and M. Godat, *J. Am. Chem. Soc.*, 1979, 101, 6441; see however the question of the stability of catalysts<sup>190</sup>.
190. S. Snipes and A.W. Herriott, *J. Am. Chem. Soc.*, 1979, 101, 6441.
191. M. Ellwood, J. Griffiths and P. Gregory, *J. Chem. Soc., Chem. Commun.*, 1980, 181.
192. H. Kobayashi, T. Sonoda, H. Iwamoto and M. Yoshimura, *Chem. Lett.*, 1979, 5, 579.
193. H. Kobayashi, T. Sonoda and H. Iwamoto, *Chem. Lett.*, 1982, 8, 1185.
194. L. Cassar, *Ann. New York Acad. Sci.*, 1980, 208.
195. H. Alper, *Adv. Organomet. Chem.*, 1981, 19, 183.
196. L. Cassar, M. Foa and A. Gardano, *J. Organomet. Chem.*, 1976, C55, 121.
197. H. Alper and H. Desabbayes, *J. Organomet. Chem.*, 1977, C11, 134.
198. H. Dasabbayes and H. Alper, *J. Am. Chem. Soc.*, 1977, 98, 99.

Received, 7th February, 1983